{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=21&state=Arizona", "query": { "state": "Arizona", "city": "Phoenix", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 8144, "total_pages": 815, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=22&state=Arizona&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=20&state=Arizona&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T21:15:48.917Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00313885", "title": "Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibromyalgia", "Sleep", "Chronic Pain" ], "interventions": [ { "name": "eplivanserin (SR46349)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 205, "start_date": "2004-04", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2010-11-30", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 11, "location_summary": "Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313885" }, { "nct_id": "NCT01305538", "title": "Crossover Post-herpetic Neuralgia (PHN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-Herpetic Neuralgia (PHN)" ], "interventions": [ { "name": "BMS-954561", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 100, "start_date": "2011-03", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Lomita, California • Boulder, Colorado + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lomita", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01305538" }, { "nct_id": "NCT02944448", "title": "A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis, Hip", "Osteoarthritis, Knee", "Arthritis", "Joint Diseases", "Musculoskeletal Diseases", "Rheumatic Diseases" ], "interventions": [ { "name": "CR845 tablet 1 mg", "type": "DRUG" }, { "name": "CR845 tablet 2.5 mg", "type": "DRUG" }, { "name": "CR845 tablet 5 mg", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cara Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 761, "start_date": "2016-09", "completion_date": "2017-06", "has_results": true, "last_update_posted_date": "2020-10-20", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02944448" }, { "nct_id": "NCT03697148", "title": "Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Carcinoma" ], "interventions": [ { "name": "Multiparametric Magnetic Resonance Imaging", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 852, "start_date": "2019-02-11", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • New Haven, Connecticut + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697148" }, { "nct_id": "NCT07652658", "title": "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis (IPF)" ], "interventions": [ { "name": "Placebo for AZD8965", "type": "OTHER" }, { "name": "AZD8965 low dose", "type": "DRUG" }, { "name": "AZD8965 medium dose", "type": "DRUG" }, { "name": "AZD8965 high dose", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 359, "start_date": "2026-06-11", "completion_date": "2028-09-14", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07652658" }, { "nct_id": "NCT05346835", "title": "Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel OOS Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 137, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05346835" }, { "nct_id": "NCT07573215", "title": "Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreas Adenocarcinoma", "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "daraxonrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 256, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 198 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07573215" }, { "nct_id": "NCT06948435", "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension", "Overweight or Obesity" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2025-04-30", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Covina, California • Northridge, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948435" }, { "nct_id": "NCT04982289", "title": "Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "ALXN1830", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-01-01", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2022-02-11", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04982289" }, { "nct_id": "NCT04877691", "title": "Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Medi-546", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 367, "start_date": "2021-06-08", "completion_date": "2026-11-06", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-17T21:15:48.917Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Cajon", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04877691" } ] }